Literature DB >> 24292108

Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment.

E K Spanakis1, D E Sellmeyer.   

Abstract

Calciphylaxis occurs rarely in the absence of end stage renal disease. Predisposing factors for nonuremic calciphylaxis (NUC) include hyperparathyroidism, coagulopathies, connective tissue disease, liver disease, glucocorticoid use, and malignancy. Warfarin can facilitate vascular calcification by reducing vitamin K-dependent carboxylation of matrix-Gla proteins. An 86-year-old Caucasian woman with a history of polymyalgia rheumatica, two spontaneous deep venous thromboses (DVTs) and multiple fractures was treated with calcium, vitamin D, prednisone, and warfarin. The patient's low bone density was treated initially with estrogen, then oral bisphosphonate, which was discontinued due to upper gastrointestinal symptoms. Nasal calcitonin was initiated. After 10 years of calcitonin treatment, she was changed to teriparatide. Two months after initiating teriparatide, she developed lower extremity edema and painful erythematous nodular lesions on her calves bilaterally, that progressed to necrotic ulcers despite antibiotic therapy. Biopsy of the lesions showed calcification in the media of small blood vessels and subcutaneous fat with fat necrosis, consistent with calciphylaxis. Teriparatide was discontinued. Aggressive wound care, antibiotics, and intravenous zoledronic acid were initiated. With cessation of teriparatide therapy and intensive wound care, the patient's lesions resolved over 8 months. We report the first case of NUC precipitated by teriparatide therapy. Our patient had multiple underlying predisposing factors including a connective tissue disorder, glucocorticoid therapy, warfarin use, and possible underlying coagulopathy given her history of multiple DVTs. In such patients, alternative osteoporosis therapies may be preferred.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292108      PMCID: PMC4096496          DOI: 10.1007/s00198-013-2580-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  20 in total

1.  Sensitization to calciphylaxis by endogenous parathyroid hormone.

Authors:  H SELYE; G GABBIANI; R STREBEL
Journal:  Endocrinology       Date:  1962-10       Impact factor: 4.736

2.  Calciphylaxis: natural history, risk factor analysis, and outcome.

Authors:  Roger H Weenig; Lindsay D Sewell; Mark D P Davis; James T McCarthy; Mark R Pittelkow
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

3.  Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'.

Authors:  Ismail A Mohammed; Vashisht Sekar; Abdullah J Bubtana; Sandip Mitra; Alastair J Hutchison
Journal:  Nephrol Dial Transplant       Date:  2007-10-02       Impact factor: 5.992

Review 4.  Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B.

Authors:  Roger H Weenig
Journal:  J Am Acad Dermatol       Date:  2008-01-18       Impact factor: 11.527

5.  Calciphylaxis in a diabetic patient provoked by warfarin therapy.

Authors:  N Asobie; E Wong; M G Cook
Journal:  Clin Exp Dermatol       Date:  2008-05       Impact factor: 3.470

Review 6.  Calciphylaxis: a systematic review of existing and emerging therapies.

Authors:  Chetan Vedvyas; Laura S Winterfield; Ruth Ann Vleugels
Journal:  J Am Acad Dermatol       Date:  2011-08-06       Impact factor: 11.527

7.  Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells--a cell system which resembles the system in bone cells.

Authors:  R Wallin; D Cain; D C Sane
Journal:  Thromb Haemost       Date:  1999-12       Impact factor: 5.249

8.  Warfarin exposure and calcification of the arterial system in the rat.

Authors:  A M Howe; W S Webster
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

9.  Successful treatment of calciphylaxis with pamidronate.

Authors:  Stefan Schliep; Gerold Schuler; Franklin Kiesewetter
Journal:  Eur J Dermatol       Date:  2008-08-08       Impact factor: 3.328

Review 10.  Calciphylaxis from nonuremic causes: a systematic review.

Authors:  Sagar U Nigwekar; Myles Wolf; Richard H Sterns; John K Hix
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

View more
  7 in total

Review 1.  Warfarin-Associated Nonuremic Calciphylaxis.

Authors:  Wesley Yung-Hsu Yu; Tina Bhutani; Rachel Kornik; Laura B Pincus; Theodora Mauro; Michael D Rosenblum; Lindy P Fox
Journal:  JAMA Dermatol       Date:  2017-03-01       Impact factor: 10.282

2.  Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment.

Authors:  A Monegal; P Peris; M Alsina; J Colmenero; N Guañabens
Journal:  Osteoporos Int       Date:  2016-03-24       Impact factor: 4.507

Review 3.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

4.  Benefits of intralesional injections of sodium thiosulfate in the treatment of calciphylaxis.

Authors:  Kirsi Isoherranen; Laura Bouchard; Nicolas Kluger
Journal:  Int Wound J       Date:  2017-03-21       Impact factor: 3.315

5.  Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide.

Authors:  T D Htet; J A Eisman; G J Elder; J R Center
Journal:  Osteoporos Int       Date:  2017-12-15       Impact factor: 4.507

6.  Periodontal and biochemical bone metabolism assessment on a chronic oral anticoagulation population treated with dicoumarins.

Authors:  D López-Lacomba; A Roa-López; M González-Jaranay; G Gómez-Moreno; G Moreu
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-03-01

7.  Non-Uremic Calciphylaxis: An Unexpected Complication With Recombinant Human Parathyroid Hormone.

Authors:  Cory DeClue; Bhavana Chinnakotla; Michael J Gardner
Journal:  Cureus       Date:  2021-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.